Potential of Mw as a prophylactic vaccine against pulmonary tuberculosis.

Potential of Mw as a prophylactic vaccine against pulmonary tuberculosis. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Potential of Mw as a prophylactic vaccine against pulmonary tuberculosis. Abstract Text:

K Katoch,Padam Singh,T Adhikari,S K Benara,H B Singh,D S Chauhan,V D Sharma,M Lavania,A S Sachan,V M Katoch,K Katoch,Padam Singh,T Adhikari,S K Benara,H B Singh,D S Chauhan,V D Sharma,M Lavania,A S Sachan,V M Katoch,

Mycobacterium w (Mw), is a cultivable, non-pathogenic mycobacterium and has been tried extensively as an immunomodulator in leprosy. This has been found to be safe and has shown beneficial immunoprophylactic effect in population based, double blind placebo controlled trials in North India. These effects were also observed in the vaccine trials in South India. Keeping in view these beneficial effects and its earlier reported protective effect against tuberculosis in animals, its protective efficacy was evaluated in a rural population of about 28,948 people belonging to 272 villages in Ghatampur, Kanpur (India). The population was vaccinated with two doses (1st dose of 1x10(9) heat killed organisms followed 6 months later with a 2nd dose of 5x10(8) organisms) of Mw 10-13 years ago originally to investigate its effect against leprosy. The vaccine/placebo was given to healthy contacts of leprosy patients who had no evidence of suffering from tuberculosis. Incidence and prevalence of pulmonary tuberculosis in the present study was assessed in a blind manner by an active field survey and also retrospectively by history of anti tuberculosis treatment received by the patient in the intervening period (since vaccination), which was also corroborated by scrutinizing the medical records. Diagnosis was confirmed by standard clinical and bacteriological criteria. A total of 69 patients were diagnosed to be suffering from pulmonary tuberculosis during the survey which included 17 new sputum smear positive cases and 52 previously partially treated but still active pulmonary tuberculosis cases. The difference in the new sputum positive cases between the vaccinated (5/17) and placebo groups (12/17) was significant at 5% level of significance for 1 tailed test (Z>1.64). As 75% (52/69) of the cases had been diagnosed as suffering from pulmonary tuberculosis but had not taken adequate therapy all the cases diagnosed during the intervening period were recorded and re-analysis done. The differences are more significant at 1% level of significance for 1 tail test (Z>2.59) when all cases were analysed as a group. A small proportion 12.85% (total number=3036) of the contacts in the study population had BCG scars. On analysis of results on protection against tuberculosis in this group, BCG did provide protection against tuberculosis (p<0.01). In the placebo group the prevalence of tuberculosis was 1.11% which reduced to 0.70% for those who received Mw vaccine (p<0.01) which further decreased to 0.53% in those who had BCG scars and received Mw. These results thus provide evidence suggesting protective efficacy of Mw against pulmonary tuberculosis and that Mw merits investigation in future prospective immunoprophylactic trials along with other candidates for protection against pulmonary tuberculosis.

Potential of Mw as a prophylactic vaccine against pulmonary tuberculosis. Publishing Authors By Initials

K Katoch,P Singh,T Adhikari,SK Benara,HB Singh,DS Chauhan,VD Sharma,M Lavania,AS Sachan,VM Katoch,K Katoch,P Singh,T Adhikari,SK Benara,HB Singh,DS Chauhan,VD Sharma,M Lavania,AS Sachan,VM Katoch,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Potential of Mw as a prophylactic vaccine against pulmonary tuberculosis. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Vaccine

VOLUME: 26

Page Numbers: 1228-34

Journal Abbreviation: Vaccine

ISSN: 0264-410X

DAY: 10

MONTH: 01

YEAR: 2008

Potential of Mw as a prophylactic vaccine against pulmonary tuberculosis. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8406899

Potential of Mw as a prophylactic vaccine against pulmonary tuberculosis. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Potential of Mw as a prophylactic vaccine against pulmonary tuberculosis. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Potential of Mw as a prophylactic vaccine against pulmonary tuberculosis.

AFFILIATION: National JALMA Institute for Leprosy and Other Mycobacterial Diseases (ICMR), Tajganj, Agra, UP 282001, India.

Country: Netherlands

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Vaccine

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Potential of Mw as a prophylactic vaccine against pulmonary tuberculosis Related Publications

• DNA fingerprinting of Mycobacterium tuberculosis isolates from Agra region by is 6110 probe.
• Effect of trikatu pretreatment on the pharmacokinetics of pefloxacin administered orally in mountain Gaddi goats.
• Isolation of Mycobacterium bovis & M. tuberculosis from cattle of some farms in north India - Possible relevance in human health.
• Molecular typing of Mycobacterium tuberculosis isolates from a rural area of Kanpur by spoligotyping and mycobacterial interspersed repetitive units (MIRUs) typing.
• Mycobacterial research in India: Successes and challenges.
• New generation methods for drug susceptibility testing for tuberculosis.
• Pathogenic rapidly growing - Mycobacterium manitobense in the environment of Agra, north India.
• Potential of Mw as a prophylactic vaccine against pulmonary tuberculosis.
• Recent advances in molecular biology of leprosy.
• Seroprevalence of HIV infection among paediatric tuberculosis patients in Agra, India: a hospital-based study.
• Tissue specific and variable collagen proliferation in Swiss albino mice treated with clenbuterol.